Products for Research Use Only

Valganciclovir-d5 (TFA)

CAT: 0804-HY-A0032SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0032SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Valganciclovir-d5 (TFA) is the deuterium labeled Valganciclovir TFA[1]. Valganciclovir, the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections[2][3][4].
CAS Number
1402924-31-5
UNSPSC
12352005
Target
CMV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Solubility
10 mM in DMSO
Smiles
OC(C(F)(F)F)=O.CC(C)[C@H](N)C(OC([2H])([2H])C(C([2H])([2H])O)([2H])OCN1C2=C(C(N=C(N2)N)=O)N=C1)=O
Molecular Formula
C16H18D5F3N6O7
Molecular Weight
473.42
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89 (6) :781-9.|[3]Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun14 (3) :259-67.|[4]O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15111 (4) :1816-9.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products